Literature DB >> 15285884

Use of the linear-quadratic radiobiological model for quantifying kidney response in targeted radiotherapy.

Roger Dale1.   

Abstract

This paper reviews the generalized application of the linear quadratic (LQ) model of radiobiological effect to targeted radiotherapy. Special attention is given to formulations for normal tissue responses and these are applied, in particular, to the kidney. Because it is derived from self-consistent bio-physical principles, the LQ model currently remains the standard formalism for assessing biological responses for the whole range of radiotherapy treatments. A central feature of the model is the derivation of biologically effective doses (BEDs), which may be used to quantify the impact of a treatment on both tumors and normal tissues. BEDs are routinely derived for conventional external-beam treatments. The likely limits of targeted radiotherapy may, thus, be assessed by comparing the expected normal-tissue BEDs for such treatments with those known to be just tolerable in conventional therapy. The main parameters required in the model are defined, and data are provided which demonstrate the tentative link between targeted radiotherapy doses and those used in conventional radiotherapy. The extension of the LQ method to targeted radiotherapy involves using parameters for which the numerical values may not be accurately known at present. This places a restriction on the overall predictive accuracy of the model and the necessary caveats are, therefore, outlined.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15285884     DOI: 10.1089/1084978041425070

Source DB:  PubMed          Journal:  Cancer Biother Radiopharm        ISSN: 1084-9785            Impact factor:   3.099


  17 in total

1.  Radiobiological considerations for radioembolization with 188Re-microspheres.

Authors:  Liane Oehme; Jörg Kotzerke
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-11-19       Impact factor: 9.236

Review 2.  Yttrium-labelled peptides for therapy of NET.

Authors:  Lisa Bodei; Marta Cremonesi; Chiara M Grana; Marco Chinol; Silvia M Baio; Stefano Severi; Giovanni Paganelli
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-02       Impact factor: 9.236

Review 3.  Three-dimensional radiobiological dosimetry (3D-RD) with 124I PET for 131I therapy of thyroid cancer.

Authors:  George Sgouros; Robert F Hobbs; Francis B Atkins; Douglas Van Nostrand; Paul W Ladenson; Richard L Wahl
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-04-12       Impact factor: 9.236

4.  90Y-DOTATOC Dosimetry-Based Personalized Peptide Receptor Radionuclide Therapy.

Authors:  Yusuf Menda; Mark T Madsen; Thomas M O'Dorisio; John J Sunderland; G Leonard Watkins; Joseph S Dillon; Sarah L Mott; Michael K Schultz; Gideon K D Zamba; David L Bushnell; M Sue O'Dorisio
Journal:  J Nucl Med       Date:  2018-03-09       Impact factor: 10.057

5.  Radioresistance of the breast tumor is highly correlated to its level of cancer stem cell and its clinical implication for breast irradiation.

Authors:  Xiangrong Sharon Qi; Frank Pajonk; Susan McCloskey; Daniel A Low; Patrick Kupelian; Michael Steinberg; Ke Sheng
Journal:  Radiother Oncol       Date:  2017-09-17       Impact factor: 6.280

6.  Radiobiological characterization of post-lumpectomy focal brachytherapy with lipid nanoparticle-carried radionuclides.

Authors:  Brian A Hrycushko; Alonso N Gutierrez; Beth Goins; Weiqiang Yan; William T Phillips; Pamela M Otto; Ande Bao
Journal:  Phys Med Biol       Date:  2011-02-07       Impact factor: 3.609

7.  Arterial wall dosimetry for non-Hodgkin lymphoma patients treated with radioimmunotherapy.

Authors:  Robert F Hobbs; Sébastien Baechler; Richard L Wahl; Bin He; Hong Song; Caroline E Esaias; Eric C Frey; Heather Jacene; George Sgouros
Journal:  J Nucl Med       Date:  2010-02-11       Impact factor: 10.057

8.  Peptide receptor radionuclide therapy with ¹⁷⁷Lu-DOTATATE: the IEO phase I-II study.

Authors:  Lisa Bodei; Marta Cremonesi; Chiara M Grana; Nicola Fazio; Simona Iodice; Silvia M Baio; Mirco Bartolomei; Dario Lombardo; Mahila E Ferrari; Maddalena Sansovini; Marco Chinol; Giovanni Paganelli
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-09-03       Impact factor: 9.236

9.  Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors.

Authors:  Lisa Bodei; Marta Cremonesi; Mahila Ferrari; Monica Pacifici; Chiara M Grana; Mirco Bartolomei; Silvia M Baio; Maddalena Sansovini; Giovanni Paganelli
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-04-22       Impact factor: 9.236

Review 10.  Peptide receptor therapies in neuroendocrine tumors.

Authors:  L Bodei; D Ferone; C M Grana; M Cremonesi; A Signore; R A Dierckx; G Paganelli
Journal:  J Endocrinol Invest       Date:  2009-04       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.